News

CMT news out of Belgium: Augustine Therapeutics has officially dosed the first participant in a Phase I clinical trial of AGT-100216, the company’s experimental drug in development for Charcot-Marie-Tooth disease (CMT). According to the company, AGT-100216 is an HDAC6 inhibitor (HDAC6i). ...

The Charcot-Marie-Tooth Association (CMTA) congratulates CMTA Strategy To Accelerate Research (CMTA-STAR) Alliance Partner Applied Therapeutics on presenting new 24-month results from its Phase III CMT-SORD clinical trial at the 2025 Annual Meeting of the Peripheral Nerve Society (PNS). The findings ...

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth (CMT) disease research, presented a new analysis of the genetic landscape of CMT at the 2025 Annual Meeting of the Peripheral Nerve Society (PNS). The poster presentation, The Genetic Landscape of ...

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research, today announced the 2025 Inherited Neuropathies Fellow through its Inherited Neuropathies Consortium (INC) alliance. The fellowship was awarded to Bopha Chrea, MD, a board-certified orthopedic surgeon at ...

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research, is proud to announce the designation of Hani Kushlaf, MD, FAAN, FANA, FAANEM, at the University of Cincinnati Gardner Neuroscience Institute in Cincinnati, Ohio, as a ...